Almost 95% of patients with MS have cerebrospinal fluid (CSF) immunoglobulin in oligoclonal patterns or bands (IgG-OB), with unusual cases of MS OB-negative: 35 to 45% in the Far East 9 . It is clear nowadays that IgG-OB demonstrate a prognostic role in the conversion to MS in clinical isolated syndrome (CIS) 10, 11 . However, in MS patients, their role in prognosis has not been completely understood. Joseph et al., in a retrospective case analysis including 100 IgG-OB negative MS patients, demonstrated that band negative patients have clinical, neuroradiological, and prognostic differences compared with positive ones 9 . These MS patients without IgG-OB in CSF were more likely to show atypical presentations at onset and a better prognosis of physical disability during follow-up. Primarily, IgG-OB negative cases were less likely to reach disability endpoints measured by the expanded disability status scale (EDSS), when compared with positive band patients, independently of magnetic resonance (MR), and other clinical features 9 . However, the exact role of IgG-OB in the prognosis of MS patients is not fully understood. In contrast to IgG-OB, it has been demonstrated that lipid-specific IgM oligoclonal bands, when present in MS patients, predict an aggressive course of the disease in terms of new relapses and cumulative disability 12, 13 . Despite the fact that IgM lipidspecific has a demonstrated role in prognosis of the disease, it is a more complex and less disseminated technique.
Considering the relevance that brain atrophy, which may be termed as neurodegeneration, might have in predicting the disease evolution at MS onset 3, 5 and the role that IgG-OB could have in producing such damage 9 , the aim of this study was to evaluate the relationship between CSF IgG-OB positivity, and the presence of brain atrophy in the MS early onset.
METHODS

Patients
This study was designed to be cross-sectional. Patients with remitting-relapsing MS (RRMS) and less than two years of disease onset (defined as the appearance of the first demyelinating symptoms compatible with MS) were included between June 2006 and June 2010 from a cohort of patients from the MS Center of the Hospital Italiano de Buenos Aires, in Argentina. For inclusion, patients had to fulfill Poser 14 or McDonald 15 criteria for dissemination in time and space for MS and were required to have a MR at onset of the disease and without taking steroid treatment for at least 30 days prior to the scan.
Clinical and paraclinical data analyzed
For patients included in the study, the clinical variables obtained included demographic data, form of clinical onset, and EDSS at the beginning of the disease. Paraclinical data obtained at onset and analyzed were: serological tests for differential diagnosis, including antinuclear antibodies, B12 vitamin and folate levels, syphilis and HIV; IgG-OB detection in CSF was performed by agarose isoelectric focusing combined with immunoblotting and avidin-biotin amplified with double antibody peroxidase staining, as well as in the serum of each patient included. Brain MR was performed on a 1.5 Tesla machine, with a standard head coil (Siemens Avanto) within two months of the first demyelinating event. Spinal MR was also performed if the CIS was a spinal cord syndrome. The MR study included images obtained in the following sequences: T1-weighted conventional spin-echo; T2-weighted fast spin-echo; FLAIR spin-echo, and T1-weighted conventional spin-echo after single doses of gadolinium (0.1 mg/kg). All images had a 5 mm section thickness and a 0.5 mm intersection gap.
Brain volume measurements
Brain volumes were estimated from T1-weighted images with SIENAX, which is a software part of the FSL library (an adaptation of SIENA for cross-sectional measurement) 16 . This software estimates the total brain parenchyma volume (TBV) and then separates it in neocortical grey matter volume (GMV), white matter volume (WMV), and CSF volume. It also estimates the brain volumes from a single image, normalized for skull size. It first strips nonbrain tissue and then uses the brain and skull images to estimate the scaling between the subject's image and standard space. Next, it runs tissue segmentation to estimate the brain tissue volume and multiplies this by the estimated scaling factor to reduce head-size-related variability between subjects 16 . In addition to brain volume measurements, T1 and T2-weighted lesion volumes at baseline were calculated. SepINRIA software was used to segment and calculate T1 and T2 lesion loads by lesion segmentation edition 17 . Ethics approval for the cross-sectional study was obtained from the Medical Ethics Committee of Hospital Italiano de Buenos Aires. Written informed consent was then obtained from all participants included in this study.
Statistical analysis
Data were stored and analyzed in STATA 9.1 software. Differences in variables between patients with and without IgG-OB were examined using Mann-Whitney's U, KruskalWallis, and Fisher's exact tests for continuous and categorical variables, respectively. A p<0.05 was considered statistically significant.
RESULTS
From a total of 114 evaluated patients, only forty met the inclusion criteria and were subsequently included in the study. Mean age of the sample was 32±5.6 years-old and mean EDSS was 1.1±0.5. Demographic, clinical, and paraclinical data of the patients included are displayed in Table 1 . Of 40 patients, 29 (72.5%) had positive IgG-OB in the CSF. No differences were found between IgG-OB positive and negative patients in gender, EDSS, time from onset of disease and treatment received, and T2 as well as T1 lesion load (Table 2) . When brain volume was measured, we observed that the TBV in positive IgG-OB patients was 1.5 mm 3 x 10 6 compared with 1.64 mm 3 x 10 6 in negative ones (p=0.02). When neocortical grey matter was evaluated, we found that the GMV was 0.51 mm 3 x 10 6 in positive IgG-OB versus 0.62 mm 3 x 10 6 in negative ones (p=0.002). WMV was 0.98 mm 3 x 10 6 in positive IgG-OB versus 1.12 mm 3 x 10 6 in negative ones (p=0.09), as seen in Table 2 and Figure. 
DISCUSSION
It is currently accepted that brain atrophy is related to neurodegeneration in MS, as well as to physical longterm disability 18 . Our study has showed that the presence of IgG-OB in CSF at the onset of MS is associated with the presence of brain volume reduction, mainly in neocortical grey matter and independently from the lesion load or other clinical parameters. No differences in lesion load volumes were found; however, an increased tendency of higher lesion load volumes in T2 in positive IgG-OB was observed, with a nearly significant difference.
Our results are in line with a recently published study, in which the presence of lipid-specific IgM-OB in the CSF was related in CIS patients to higher lesion load, higher brain atrophy during the short-term follow-up, and increased probability of conversion to MS compared with patients without this biomarker 19 . A possible explanation could be that the presence of Ig in the CSF, independently of whether it is IgG or IgM, is related to an immunological phenomenon that may be producing brain tissue damage, which would consequently lead to a reduction in measured volumes. Studies are currently demonstrating that the reduction in brain volume (brain atrophy) is related to physical disability in the short and mid-term follow-ups, with this marker being considered as a possible biomarker in the near future that may help to predict the course of the disease in MS patients 3, 5, 18, 19 . On the other hand, the reduction of brain volumes in MS patients could be related to other unexplored and unknown phenomena like reduction of the inflammation (pseudoatrophy) instead of neurodegeneration. However, current evidences move brain atrophy evidences towards neurodegeneration and axonal loss instead of preservation 5, 19, 20 . Undoubtedly, future studies will elucidate this issue. 
